Back to Search
JAE KIM, MD
MD
Emergency Medicine Physician
NPI: 1407831472Individual
Specialties, Licenses & Credentials
Emergency Medicine PhysicianPrimary
Emergency Medicine
Code: 207P00000X
133905(NY)
Clinical Trials (1)
1
Linked Trials
0
Recruiting
0
With Results
Research & Publications (20)
Psoriasis harbors multiple pathogenic type 17 T-cell subsets: Selective modulation by risankizumab.
PMID 39978685·J Allergy Clin Immunol·2025
8-other
Proportion of CD4CD49bLAG-3Type 1 Regulatory T Cells in the Blood of Psoriasis Patients Inversely Correlates with Psoriasis Area and Severity Index.
PMID 29890167·J Invest Dermatol·2018
8-other
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
PMID 30097359·Lancet·2018
3-trial
Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment.
PMID 28927890·J Invest Dermatol·2018
3-trial
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
PMID 28423301·N Engl J Med·2017
3-trial
Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis.
PMID 27686018·Annu Rev Med·2017
6-review
The Spectrum of Mild to Severe Psoriasis Vulgaris Is Defined by a Common Activation of IL-17 Pathway Genes, but with Key Differences in Immune Regulatory Genes.
PMID 27185339·J Invest Dermatol·2016
4-observational
Molecular Phenotyping Small (Asian) versus Large (Western) Plaque Psoriasis Shows Common Activation of IL-17 Pathway Genes but Different Regulatory Gene Sets.
PMID 26763436·J Invest Dermatol·2016
4-observational
Patients With Psoriasis and Personalized Trade-offs in Treatment Decisions-Lessons Learned From Focus Groups.
PMID 27028481·JAMA Dermatol·2016
8-other
Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial.
PMID 25769911·J Allergy Clin Immunol·2015
2-rct
Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris.
PMID 14707118·J Exp Med·2004
4-observational
Medial-to-lateral laparoscopic colon resection: a view beyond the learning curve.
PMID 17641928·Surg Endosc·2007
8-other
Effect of human bone marrow stromal cell allograft on proliferation and collagen synthesis of diabetic fibroblasts in vitro.
PMID 19419913·J Plast Reconstr Aesthet Surg·2010
8-other
Fabrication of biodegradable nanofibers of poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) via electrospinning.
PMID 19441421·J Nanosci Nanotechnol·2009
8-other
RAD6-Mediated transcription-coupled H2B ubiquitylation directly stimulates H3K4 methylation in human cells.
PMID 19410543·Cell·2009
7-preclinical
The catalytic effect of Pt nanoparticles supported on silicon oxide nanowire.
PMID 19448290·Nanotechnology·2009
8-other
Comparison of antioxidant activity in wild plant (Adenophora triphylla) leaves and roots as a potential source of functional foods.
PMID 19462329·Int J Food Sci Nutr·2009
4-observational
Direct deposition of size-tunable Au nanoparticles on silicon oxide nanowires.
PMID 19477456·J Colloid Interface Sci·2009
8-other
Preparation of biodegradable polymer/silver nanoparticles composite and its antibacterial efficacy.
PMID 19441464·J Nanosci Nanotechnol·2009
8-other
Compassionate attitude towards others' suffering activates the mesolimbic neural system.
PMID 19428038·Neuropsychologia·2009
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 451 CLARKSON AVE
BROOKLYN, NY 11203 - Phone
- (718) 245-3362
Quick Facts
- NPI
- 1407831472
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Clinical Trials
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile